Recent studies suggest that shorter, high-dose radiation treatments can be just as effective as longer-range therapy regimens. So, why aren’t more patients opting for them? According to doctors at Duke University Medical Center, that reason could be cost.
Duke’s research shows that fewer than 20 percent of patients with early invasive breast cancer who opted for breast-conserving surgery chose to receive the shorter hydrofractionated therapy instead of the more traditional therapy. Researchers at the San Antonio Breast Cancer Symposium reported that concerns over cost could be the reason shorter, high-dose therapies aren’t catching on. They also note that about 10 percent of patients at community facilities have access to the hydrofractionated radiation and some 15 percent of patients treated at comprehensive community cancer centers received the treatment.
You can read more about short course radiation therapy in the latest edition of the PBCC’s Frontline Newsletter here.
To read more about this study online, click here.